Fleischman, Angela Goffred

TitleAssistant Professor
InstitutionUniversity of California, Irvine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(949) 824-2559
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Singer JW, Fleischman A, Al-Fayoumi S, Mascarenhas JO, Yu Q, Agarwal A. Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget. 2018 Sep 07; 9(70):33416-33439. PMID: 30279971.
      View in: PubMed
    2. Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, Fleischman AG, O'Brien S, Lam LT, Leverson JD, Letai A, Schatz JH, Fruman DA. Statins enhance efficacy of venetoclax in blood cancers. Sci Transl Med. 2018 Jun 13; 10(445). PMID: 29899021.
      View in: PubMed
    3. Craver BM, El Alaoui K, Scherber RM, Fleischman AG. The Critical Role of Inflammation in the Pathogenesis and Progression of Myeloid Malignancies. Cancers (Basel). 2018 Apr 03; 10(4). PMID: 29614027.
      View in: PubMed
    4. Zhang J, Fleischman AG, Wodarz D, Komarova NL. Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms. J Theor Biol. 2017 Jul 21; 425:43-52. PMID: 28501635.
      View in: PubMed
    5. Nguyen TK, Morse SJ, Fleischman AG. Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm. J Vis Exp. 2016 12 22; (118). PMID: 28060252.
      View in: PubMed
    6. Brooks SA, Luty SB, Lai HY, Morse SJ, Nguyen TK, Royer LR, Agarwal A, Druker BJ, Fleischman AG. JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model. Exp Hematol. 2016 Jan; 44(1):24-9.e1. PMID: 26458983.
      View in: PubMed
    7. Fleischman AG. Inflammation as a Driver of Clonal Evolution in Myeloproliferative Neoplasm. Mediators Inflamm. 2015; 2015:606819. PMID: 26538830; PMCID: PMC4619974.
    8. Afrasiabi K, Zhou YH, Fleischman A. Chronic inflammation: is it the driver or is it paving the road for malignant transformation? Genes Cancer. 2015 May; 6(5-6):214-9. PMID: 26124920; PMCID: PMC4482242.
    9. Agarwal A, Mackenzie RJ, Besson A, Jeng S, Carey A, LaTocha DH, Fleischman AG, Duquesnes N, Eide CA, Vasudevan KB, Loriaux MM, Firpo E, Cortes JE, McWeeney S, O'Hare T, Roberts JM, Druker BJ, Deininger MW. BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein. Blood. 2014 Nov 20; 124(22):3260-73. PMID: 25293778; PMCID: PMC4239335.
    10. Fleischman AG, Tyner JW. Causal role for JAK2 V617F in thrombosis. Blood. 2013 Nov 28; 122(23):3705-6. PMID: 24288407; PMCID: PMC3843232.
    11. Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, MacManiman JD, Loriaux MM, Druker BJ, Tyner JW. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013 Nov 21; 122(22):3628-31. PMID: 24081659; PMCID: PMC3837511.
    12. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, Chang BH, Loriaux MM, Druker BJ, Tyner JW. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013 May 09; 368(19):1781-90. PMID: 23656643; PMCID: PMC3730275.
    13. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberg DS, Levine RL, Moriggl R, Müller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov. 2013 May; 3(5):564-77. PMID: 23471820; PMCID: PMC3651770.
    14. Fleischman AG, Maziarz RT. Hematopoietic stem cell transplantation for myelofibrosis: where are we now? Curr Opin Hematol. 2013 Mar; 20(2):130-6. PMID: 23314844.
      View in: PubMed
    15. Agarwal A, Fleischman AG, Petersen CL, MacKenzie R, Luty S, Loriaux M, Druker BJ, Woltjer RL, Deininger MW. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood. 2012 Sep 27; 120(13):2658-68. PMID: 22889761; PMCID: PMC3460687.
    16. Fleischman AG, Tyner JW. JAK2 V617F down-modulates MPL. Blood. 2012 May 17; 119(20):4579-80. PMID: 22596167.
      View in: PubMed
    17. Fleischman AG. ALDH marks leukemia stem cell. Blood. 2012 Apr 12; 119(15):3376-7. PMID: 22500050.
      View in: PubMed
    18. Fleischman AG, Aichberger KJ, Luty SB, Bumm TG, Petersen CL, Doratotaj S, Vasudevan KB, LaTocha DH, Yang F, Press RD, Loriaux MM, Pahl HL, Silver RT, Agarwal A, O'Hare T, Druker BJ, Bagby GC, Deininger MW. TNFa facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011 Dec 08; 118(24):6392-8. PMID: 21860020; PMCID: PMC3236121.
    19. Bagby GC, Fleischman AG. The stem cell fitness landscape and pathways of molecular leukemogenesis. Front Biosci (Schol Ed). 2011 Jan 01; 3:487-500. PMID: 21196392.
      View in: PubMed
    20. Aichberger KJ, Fleischman AG, Deininger MW. Same mutation, different allele. Blood. 2009 Oct 01; 114(14):2853-4. PMID: 19797527.
      View in: PubMed